Biotech · Private company
Mimetogen Pharmaceuticals USA, Inc.
Track this companyFree. Adds Mimetogen Pharmaceuticals USA, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials60 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- 1% Tavilermide Ophthalmic SolutionPhase 3 · Keratoconjunctivitis SiccaClinicalTrials.gov · fetched Nov 12, 2026
- 5% Tavilermide ophthalmic solutionPhase 3 · Dry Eye SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- MIM-D3 Ophthalmic SolutionPhase 3 · Dry Eye SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- Tavilermide ophthalmic solutionPhase 3 · Keratoconjunctivitis SiccaClinicalTrials.gov · fetched Nov 12, 2026
- VehiclePhase 3 · Dry Eye SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle ophthalmic solutionPhase 3 · Dry Eye SyndromesClinicalTrials.gov · fetched Nov 12, 2026
- MIM-D3 Ophthalmic SolutionPhase 2 · Dry EyeClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry EyePHASE3 · COMPLETED · started Jun 28, 2023ClinicalTrials.gov NCT05848128 · fetched Nov 12, 2026
- Tavilermide Ophthalmic Solution for the Treatment of Dry EyePHASE3 · COMPLETED · started Mar 28, 2019ClinicalTrials.gov NCT03925727 · fetched Nov 12, 2026
- A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye DiseasePHASE3 · COMPLETED · started Jan 1, 2016ClinicalTrials.gov NCT02665234 · fetched Nov 12, 2026
- A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry EyePHASE3 · COMPLETED · started Dec 1, 2015ClinicalTrials.gov NCT02634853 · fetched Nov 12, 2026
- A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry EyePHASE3 · COMPLETED · started Oct 1, 2013ClinicalTrials.gov NCT01960010 · fetched Nov 12, 2026
- Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry EyePHASE2 · COMPLETED · started Nov 1, 2010ClinicalTrials.gov NCT01257607 · fetched Nov 12, 2026